IDIS to Sponsor Inaugural Conference on Pre-Launch Access to Drugs

    LONDON, Sept. 18 /PRNewswire/ -- IDIS, the world leader in the
 development and implementation of Named Patient Programs (NPPs), will
 sponsor the first-of-its-kind conference on pre-launch access to drugs in
 Baltimore, MD, on October 22-23. This conference will bring together
 industry experts to present and exchange information on programs that
 enable patients with unmet medical needs to get access to drugs in the
 pre-launch phase. Industry leaders will discuss the fundamentals of
 US-based expanded access programs (EAPs) and global named patient programs,
 the best strategies for development of such programs, the optimal timing
 for programs, and their overall management.
 
     Internet access to information about drugs in late-stage clinical
 trials or approvals in certain countries has created a more informed and
 empowered population of patients who are taking a more aggressive approach
 to their health. This has brought about an increased demand for access to
 pre-launch drugs amongst patients when all other therapeutic options have
 been exhausted. Fortunately, government sanctioned EAPs and NPPs are in
 place to help drug developers respond to such requests.
 
     This conference, produced by the Center for Business Intelligence
 (CBI), is geared towards pharmaceutical and biotechnology company decision
 makers from global brand groups, regulatory, medical affairs,
 supply/logistics and other functions involved in patient access programs.
 The conference will provide a forum by which these companies can learn how
 these programs benefit patients as well as the sponsoring company, as well
 as the best way to execute these programs to ensure they are conducted in a
 manner consistent with regulations that vary by country. It will also offer
 extensive opportunities for networking and discussion with senior policy
 and decision makers.
 
 

     Registration is currently being accepted at:
     https://www.cbireg.com/webreg/RegGate.wbr?PC08093 .
 
     Additional information about the conference is available at:
     http://www.cbinet.com/show_conference.cfm?confCode=PC08093 .
     About IDIS
 
     Founded in 1987, IDIS is the global leader in the development,
 implementation, and management of strategic solutions that provide access
 to unlicensed medicines across global markets via Named Patient Programs.
 Pharmaceutical and biotechnology companies of all sizes partner with IDIS
 to provide patients with genuine, unmet medical need access to potentially
 life-saving medicines.
 
 

     IDIS is headquartered near central London.
     Visit the IDIS website at http://www.idispharma.com .
     About CBI (www.cbinet.com)
 
     A subsidiary of Advanstar Communications, CBI Research, Inc. is
 dedicated to developing market-driven, unbiased conferences in
 pharmaceuticals\biotech, medical devices, risk and insurance and managed
 care markets. CBI Research, Inc. offers conferences and summits that serve
 senior executives and government officials by providing a unique platform
 for highly focused content and presentation.
 
 

     For further information on IDIS contact:
     Lynn Blenkhorn
     Feinstein Kean Healthcare
     (508) 851-0930
 
 

SOURCE IDIS